The influence of physicochemical properties on the reactivity and stability of acyl glucuronides^†

References

• Baba A, Yoshioka T. (2009a). Structure–activity relationships for degradation reactions of l-β-O-acyl glucuronides: kinetic description and prediction of intrinsic electrophilic reactivity under physiological conditions. Chem Res Toxicol 22:158–72
   PubMed Web of Science ®Google Scholar
• Baba A, Yoshioka T. (2009b). Structure-activity relationships for the degradation reactions of 1-β-O-acyl glucuronides. Part 3: electronic and steric descriptors predicting the reactivity of aralkyl carboxylic acid 1-O-acyl-β-glucuronides. Chem Res Toxicol 22:1998–2008
   PubMed Web of Science ®Google Scholar
• Ballatore C, Huryn DM, Smith AB. (2013). Carboxylic acid (bio)isosteres in drug design. ChemMedChem 8:385–95
   PubMed Web of Science ®Google Scholar
• Berry NG, Iddon L, Iqbai M, et al. (2009). Synthesis, transacylation kinetics and computational chemistry of a set of arylacetic acid 1-O-β-acyl glucuronides. Organ Biomol Chem 7:2525–33
   PubMed Web of Science ®Google Scholar
• Birch AM, Birtles S, Buckett LK, et al. (2009). Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. J Med Chem 52:1558–68
   PubMed Web of Science ®Google Scholar
• Bolze S, Bromet N, Gay-Feutry C, et al. (2002). Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metabol Dispos 30:404–13
   PubMed Web of Science ®Google Scholar
• Chabot GG, Gouyette A. (1991). Reactivity of flavone acetic acid and its acyl glucuronide. Biochem Pharmacol 42:1145–8
   PubMed Web of Science ®Google Scholar
• Darnell M, Weidolf L. (2013). Metabolism of xenobiotic carboxylic acids: focus on coenzyme A conjugation, reactivity and interference with lipid metabolism. Chem Res Toxicol 26:1139–55
   PubMed Web of Science ®Google Scholar
• Ebner T, Wagner K, Wienen W. (2010). Dabigatran acylglucuronide, the major human metabolite of dabigatran: In vitro formation, stability, and pharmacological activity. Drug Metabol Dispos 38:1567–75
   PubMed Web of Science ®Google Scholar
• Gauthier C, Legault J, Rondaeu-Gagne S, Pischette A. (2009). Synthesis of betulinic acid acyl glucuronide for application in anticancer prodrug monotherapy. Tetrahed Lett 50:988–91
   Web of Science ®Google Scholar
• Graham GG, Roberts MS, Day RO, Rainsford KD. (2004). Pharmacokinetics and Metabolism of Salicylates. In: Rainsford KD, ed. Aspirin and related drugs. London (UK): CRC Press/Taylor and Francis, 97–155
   Google Scholar
• Hanson GR. (2000). Analgesic, antipyretic, and anti-inflammatory drugs. In: Gennaro AR, ed. Remington: the science and practice of pharmacy. Philadelphia (PA): Lipincott Williams and Wilkins, 1460
   Google Scholar
• Harbourt D. (2009). An investigation into the role of glucuronidation on the disposition and toxicity of mycophenolic acid using targeted quantitative proteomics [PhD dissertation]. University of North Carolina, USA, p. 49
   Google Scholar
• Hutt AJ, Caldwell J. (1990). Amino acid conjugation. In: Mulder G, ed. Conjugation reactions in drug metabolism. An integrated approach. London (UK): Taylor and Francis, 273–305
   Google Scholar
• Iddon L, Richards SE, Johnson CH, et al. (2011). Synthesis of a series of phenylacetic acid 1-β-O-acyl glucosides and comparison of their acyl migration and hydrolysis kinetics with the corresponding acyl glucuronides. Organ Biomol Chem 9:926–34
   PubMed Web of Science ®Google Scholar
• Inoue NR, Hall A, Lai WG, Williams ET. (2013). Reversible inhibition of human carboxylesterases by acyl glucuronides. Drug Metab Dispos 41:698–703
   PubMed Web of Science ®Google Scholar
• Iwamura A. (2016). In vitro and in vivo toxicological evaluation of acyl glucuronides [PhD thesis]. Kanazawa University, Japan, 17
   Google Scholar
• Johnson CH, Karlsson E, Sarda S, et al. (2010). Integrated HPLC-MS and 1H-NMR spectroscopic studies on acyl migration reaction kinetics of model drug ester glucuronides. Xenobiotica 40:9–23
   PubMed Web of Science ®Google Scholar
• Khan S, Teitz DS, Jermal M. (1998). Kinetic analysis by HPLC-electrospray mass spectrometry of the pH-dependent acyl migration and solvolysis as the decomposition pathways of Ifetroban 1-O-acyl glucuronide. Anal Chem 70:1622–8
   Web of Science ®Google Scholar
• Knights KM, Sykes MJ, Minors JO. (2007). Amino acid conjugation: contribution to the metabolism and toxicology of xenobiotic carboxylic acids. Exp Opin Drug Metabol Toxicol 3:159–68
   PubMed Web of Science ®Google Scholar
• Lassila T, Hokkanen J, Aatsinki S-M, et al. (2015). Toxicity of carboxylic acid-containing drugs: the role of acyl migration and CoA conjugation investigated. Chem Res Toxicol 28:2292–303
   PubMed Web of Science ®Google Scholar
• McKinnon GE, Dickinson R. (1989). Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. Res Commun Chem Pathol Pharmacol 3:1033–9
   Google Scholar
• Meng X, Maggs JL, Pryde DC, et al. (2007). Cyclization of the acyl glucuronide metabolite of a neutral endopeptidase inhibitor to an electrophilic glutarimide: synthesis, reactivity, and mechanistic analysis. J Med Chem 50:6165–76
   PubMed Web of Science ®Google Scholar
• Miners JO, Valente L, Lillywhite KJ, et al. (1997). Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 57:284–9
   PubMed Web of Science ®Google Scholar
• Nicholls AW, Akira K, Lindon JC, et al. (1996). NMR Spectroscopic and theoretical chemistry studies on the internal acyl migration reactions of the 1-O-acyl-β-D-glucopyranuronate conjugates of 2-, 3- and 4-(trifluoromethyl)benzoic acids. Chem Res Toxicol 9:1414–24
   PubMed Web of Science ®Google Scholar
• Parkinson A, Ogilvie BW, Paris BL, et al. (2010). Biotransformation. In: Nasser AF, ed. Biotransformation and metabolite elucidation in xenobiotics: characterisation and identification. Hoboken (NJ): John Wiley, 1–77
   Google Scholar
• Prueksaritanont T, Subramanian R, Fang X, et al. (2001). Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505–12
   Web of Science ®Google Scholar
• Sallustio BC, Knights KM, Roberts BJ, Zacest R. (1995). In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins. Biochem Pharmacol 42:1421–5
   Web of Science ®Google Scholar
• Sawamura R, Okudaira N, Watanabe K, et al. (2010). Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos 38:1857–64
   PubMed Web of Science ®Google Scholar
• Shipkova M, Schutz E, Armstrong VW, et al. (2000). Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 46:365–72
   PubMed Web of Science ®Google Scholar
• Shore LJ, Fenselau C, King AR, Dickenson RG. (1995). Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos 23:119–23
   PubMed Web of Science ®Google Scholar
• Skopp G, Pötsch L. (2002). Stability of 11-nor-delta(9)-carboxy-tetrahydrocannabinol glucuronide in plasma and urine assessed by liquid chromatography-tandem mass spectrometry. Clin Chem 48:301–6
   PubMed Web of Science ®Google Scholar
• Smith PC, McDonagh AF, Benet LZ. (1986). Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J Clin Invest 77:934–9
   PubMed Web of Science ®Google Scholar
• Smith PS, Hasegawa J, Langendijk PNJ, Benet LZ. (1985). Stability of acyl glucuronides in blood, plasma, and urine: studies with zomepirac. Drug Metab Dispos 13:110–2
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Li C, Benet LZ. (2007). Mechanistic role of acyl glucuronides. In:Kaplowitz K, DeLeve LD, eds. Drug-induced liver disease (2nd edition). New York (NY): Marcel Dekker Inc., 135
   Google Scholar
• Stachulski A. (2014). Contemporary medicinal chemistry of glucuronides, DMPK Meeting Royal Society of Chemistry, London. Available from: http://www.rsc.org/images/AndrewStachulskitcm18-239217.pdf
   Google Scholar
• Steventon GB, Hutt AJ. (2002). The amino acid conjugations. In: Ioannides C, ed. Enzyme systems that metabolise drugs and other xenobiotics. Chichester (UK); John Wiley & Sons, 501–520
   Google Scholar
• Wen Z, Stern ST, Martin DE, et al. (2006). Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3′,3′-dimethylsuccinyl)betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma. Drug Metabol Dispos 34:1436–42
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Baba A. (2009). Structure–activity relationships for the degradation reaction of 1-β-O-acyl glucuronides. Part 2: Electronic and steric descriptors predicting the reactivity of 1-β-O-acyl glucuronides derived from benzoic acids. Chem Res Toxicol 22:1559–69
   PubMed Web of Science ®Google Scholar
• Zhang D, Raghavan N, Wang L, et al. (2011). Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment. Drug Metabol Dispos 39:123–31
   PubMed Web of Science ®Google Scholar